Phase I dose escalation and expansion study of golidocitinib, a highly selective JAK1 inhibitor, in relapsed or refractory peripheral T-cell lymphomas
Yuqin Song, Dok Hyun Yoon, Haiyan Yang, Junning Cao, Dongmei Ji, Youngil Koh, Hongmei Jing, Hyeon‐Seok Eom, Jae‐Yong Kwak, W. Robert Lee, J. Lee, Ho‐Jin Shin, Jie Jin, Michael Wang, Zhi Yang, Woo Seob Kim, Jun Zhu
Topics & Concepts
MedicineTolerabilityInternal medicineAdverse effectNeutropeniaOncologyPharmacologyJanus kinaseGastroenterologyChemotherapyCytokineLymphoma Diagnosis and TreatmentT-cell and Retrovirus StudiesCytokine Signaling Pathways and Interactions